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discontinued medication. The most commonly cited reason for
discontinuation was the medication(s) did not work well (35%);
side effects was the second most common reason (20%). Addi-
tional reasons included lack of need for frequent use (17%), cost
of treatments (11%), and dislike of taking pills all the time
(12%). When asked about medication-taking behaviors, 155
(21%) out of 752 patients taking oral medications reported skip-
ping doses. Reasons for skipping doses included forgetting to
take medication (68%), dislike of taking pills all the time (14%),
and cost of medication (10%). Of those reporting skipping doses
of medications, 41% reported this occurs every couple of weeks;
30% and 25% reported it occurs weekly and monthly respec-
tively. Only 4% reported daily skipping of doses. CONCLU-
SIONS: A signiﬁcant portion of BPH patients using oral
treatments reported discontinuing therapy due to lack of efﬁcacy
and a variety of other reasons. Skipping doses was also a
problem for over 20% of patients taking oral medications.
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OBJECTIVES: The objective of the present study is to describe
the compliance observed with a prescribed once a day placebo
over a 28 days period in adolescent healthy volunteers, in school-
dwelling youngsters in Belgium. METHODS: Eighty students
were asked to take a placebo once a day during 28 days. Tablets
supply was dispensed by sequences of 14 days either in an elec-
tronic pill box (MEMS®) or in an electronic blister pack
(Cerepak®) according to a crossover design. Both devices
allowed real time electronic compilation of dosing histories. At
the end of the study, students were asked to assess their own
compliance with a structured questionnaire. RESULTS: Compli-
ance data were available for 78 students. We observed no dif-
ference in compliance between the two monitoring devices (p =
0.682), nor between periods (p = 0.462), and no carry-over
effects (p = 0.599). 46% of the students took most of their doses
in the morning (before 10:00AM) and 49% in the evening (after
04:00PM). Compliance was higher (p = 0.016) among the stu-
dents who took their pills in the morning (92% vs 85%). Only
9 (11%) students took all of the 28 prescribed doses and 36
(46%) missed more then 5 doses. There was a strong weekend
effect. The probability to take a tablet on a Friday or a Satur-
day was reduced by 30% (p < 0.0001). Only 58% of the sub-
jects were able to estimate reasonably well their compliance with
the prescribed regimen. CONCLUSIONS: To be compliant with
drug therapy is a burden for the majority of adolescents, most
of whom are in good health and have little experience with
taking medicines. Evening and weekend discipline seems to be
problematic. No differences in compliance by measuring device
were observed. When precise assessment of compliance is crucial
for the interpretation of study results, electronic monitoring
should be used, especially in adolescent populations.
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OBJECTIVES: The recall period associated with any patient-
reported outcome (PRO) measure is critical to the interpretation
of the measure. However, the most appropriate recall period is
often unclear. The objective of this analysis was to compare
responses to two satisfaction with sexual intercourse (SSI) mea-
sures with different recall periods. METHODS: Sexual health
data and intravaginal ejaculatory latency time (IELT) were col-
lected from 1115 men and their female partners as a part of a
two-month observational study of men with and without pre-
mature ejaculation (PE) from ﬁve European countries. Data from
men diagnosed with PE are included in this analysis (n = 196).
IELT was measured by a female-operated stopwatch and
recorded by the male subject on an event log. Two single-item
measures of SSI were collected: 1) “Over the past month, was
your satisfaction with sexual intercourse: 0 = very poor, 1 = poor,
2 = fair, 3 = good, or 4 = very good?” and 2) “Were you satis-
ﬁed overall with this sexual experience?” (yes/no). Responses to
the ﬁrst item were recorded by the male subjects at the study site.
The second measure was assessed following each sexual inter-
course and recorded on the event log along with the IELT. For
this per-event item, a mean percentage SSI was computed for
each subject over a one-month period so that the recall periods
for the two measures were comparable. RESULTS: There was a
strong association between SSI measures based on one-month
recall and the percentage of satisfactory sexual experiences based
on the event log data: Very poor (Mean = 12.6%, SD = 29.4%,
n = 11), Poor (Mean = 24.0%, SD = 19.0%, n = 49), Fair (Mean
= 63.7%, SD = 25.0%, n = 66), Good (Mean = 85.6%, SD =
16.8%, n = 52) and Very good (Mean = 95.6%, SD = 7.3%, n
= 18). CONCLUSIONS: Measures of SSI assessed on a per-event
basis and using a one-month recall period are highly associated
suggesting that either measure could be used to assess outcomes
related to SSI among men with PE.
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OBJECTIVES: To evaluate barriers to communication about
erectile dysfunction (ED) and their impact on patient-reported
outcomes. METHODS: Male participants in the May 2004
internet-based National Health and Wellness Survey (NHWS)
who reported being married/living with a partner, difﬁculty
achieving/maintaining an erection but had not spoken with a
physician about ED, and taking medication for blood pressure
were recontacted in December 2004. Patients were asked
whether they had spoken with a physician about ED since the
May 2004 survey and barriers to communication about ED. ED
status and severity were conﬁrmed with the Erectile Function
(EF) domain of the International Index of Erectile Function. Data
were also collected from the SF-8, Erectile Distress Scale (EDS),
and the 2004NHWS. RESULTS: Of the 233 ED patients who
were recontacted and completed the questionnaire, 31%
reported speaking with their physician about ED. Patients who
spoke (vs did not speak) with their physician were younger (63
vs 67y, P = 0.008), had less severe ED (EF domain score, 12.1
vs 7.7, P < 0.001), and were more distressed about ED (EDS
scores, 4.1 vs 4.7, P = 0.002). Among those who spoke with their
physician, 83% initiated the discussion, and the most common
motivator was their spouse; 32% reported currently taking a
phosphodiesterase type 5 inhibitor. Fifty-seven percent of these
patients waited ≥1 year before discussing ED with their physi-
cian, most commonly because of a belief that ED was a natural
part of aging (42%). Of those who did not speak with their
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physician, 45% reported interest in an ED treatment, and 72%
believed that physicians should routinely inquire about ED.
CONLCUSIONS: Although most ED patients reported not
speaking with their physician, almost half were interested in
treatment. Patients reported initiating ED discussions more often
than physicians; however, the majority felt that physicians should
routinely ask about sexual function.
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OBJECTIVE: To interview men with BPH to determine their
expectations regarding treatment. Collection of demographic
data, International Prostate Symptom Score (IPSS), bother score,
and patient satisfaction information are standard outcome mea-
sures that provide contextual information for reviewing patient
expectations. METHODS: Multiple individual subject inter-
views were conducted at 4 geographically dispersed sites in the
US. Subjects with diagnosed BPH who met entry were included.
Research subjects completed the IPSS, BPH “bother score”,
general health questionnaires, and provided up to two top expec-
tations from treatment of BPH. Patients were thoroughly
debriefed on their answers to clarify unclear responses.
RESULTS: Thirty-seven subjects who met the criteria were inter-
viewed as part of the qualitative research. The mean age was 66
years [range, 45–82 years] and the mean IPSS score was 20
[range, 7–31]. Subjects reported a mean Bother Score of 3.1.
Thirty-ﬁve subjects (95%) reported a primary expectation for
treatment, and 26 subjects (70%) expressed primary and sec-
ondary expectations from treatment. Thirty-one subjects (89%)
expressed symptom relief as their primary expectation, followed
by reduced, or no side-effects from treatment (9%). Detailed
primary expectations included reduction in abnormal urination
(31%), reduction in frequency (20%), and reduction in nocturia
(17%). Similarly, 88% patients reported symptom relief as their
top secondary expectation. Urine control (35%), reduction in
frequency (15%), lack of sexual side-effects (8%) and reduction
in nocturia (8%) were among the top secondary expectations
from BPH treatment. CONCLUSIONS: This research indicates
that men with BPH primarily expect treatments to relieve symp-
toms. Most symptoms were identical to over-active bladder in
females. The results from this small qualitative research study
will help inform future selection of optimal measurement 
instruments for subjects in clinical trials and in routine clinical
practice.
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OBJECTIVE: To develop a questionnaire that focuses on patient
satisfaction with treatment for BPH symptoms. There are no
current questionnaires that focus on this important patient-
reported outcome. METHODS: Multiple individual subject
interviews (ISI’s) with patients currently or recently receiving
treatment for BPH was conducted to ﬁnalize content for a patient
satisfaction with treatment questionnaire. Patients selected were
required to have a diagnosis of BPH. and an IPSS total score of
greater than or equal to seven. Interviews were conducted using
an initial pool of items developed from previous patient research.
The literature was also utilized to complement item selection.
Open-ended questions about their disease and its impact were
conducted to assess missing content in the questionnaire. Sub-
jects were debriefed thoroughly on satisfaction with content,
vocabulary, and item. RESULTS: Twelve patients were inter-
viewed and a total of 13 questions were developed from this
research. The mean age was 62.3yrs (range 54–72yrs) with
majority being Caucasian males (92%) with various levels of
education. Mean IPSS score was 20.58 (range 14–30). The ﬁnal
questionnaire developed utilized a 5-point Likert scale with some
questions including a 6th option for “does not apply”. The
content of the ﬁnal questionnaire ranged from medication impact
on various symptoms of BPH, including over-active bladder type
symptoms of frequency, urgency, and nocturia. Activity impact
was also signiﬁcant and included impact of medication on ability
to interact more freely in social situations, impact on travel,
activities, and relationships (family and sexual). Cost and side
effects were also issues that concerned many of the subjects and
were included in the ﬁnal questionnaire. CONCLUSIONS: The
13-item ﬁnal questionnaire (BPH-PSTQ) generated after ISIs
with 12 subjects was easily understood by subjects in this qual-
itative development research. The content was also found to be
comprehensive of subjects concerns and major issues.
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OBJECTIVES: The factor structure of the BPH-PSTQ was eval-
uated. METHODS: A cross sectional survey was conducted with
BPH subjects that included the BPH-PSTQ. Exploratory factor
analysis was conducted using maximum likelihood estimation
and MINRES. Many criteria were evaluted to assess the number
of factors including scree plots, the number of factors with eigen-
values greater then one, proportion of variance explained by
factors, and various oblique and orthogonal rotations of the
initial unrotated solution. RESULTS: A total of 768 subjects had
complete data for analysis. The initial unrotated solution using
maximum likelihood estimation left two factors with eigenval-
ues greater then one (25.2, 1.7). The variance explained by the
dominant factor in the unrotated solution was 93%. Signiﬁcance
tests suggested that more then two factors were needed based
upon chi-square results. Analysis of scree plot results demon-
strated that there was one dominant factor and possibly a second
factor that could be considered before there was a signicant
plateau on the plot. Quartimax rotation demonstrated a one
factor solution with questions 11 and 13 not loading very highly
on the dominant factor (0.54, 0.53). Final communality estimate
were also not as good for these two items. Other rotations con-
ﬁrmed the misﬁt of item 13. CONCLUSIONS: The unidimen-
sionality of the BPH-PSTQ needs to be further explored to
determine if there are multiple underlying factors with sub-scales
or multiple distinct factors via conﬁrmatory factor analysis mod-
eling. Item 13 was the only item that did not seem to ﬁt with
any of the other items in the scale, and did not load well on any
latent factors.
